SOD1
protein-codingsuperoxide dismutase 1, the group of Superoxide dismutases
Gene summary
The protein encoded by this gene binds copper and zinc ions and is one of two isozymes responsible for destroying free superoxide radicals in the body. The encoded isozyme is a soluble cytoplasmic protein, acting as a homodimer to convert naturally-occuring but harmful superoxide radicals to molecular oxygen and hydrogen peroxide. The other isozyme is a mitochondrial protein. In addition, this protein contains an antimicrobial peptide that displays antibacterial, antifungal, and anti-MRSA activity against E. coli, E. faecalis, S. aureus, S. aureus MRSA LPV+, S. agalactiae, and yeast C. krusei. Mutations in this gene have been implicated as causes of familial amyotrophic lateral sclerosis. Rare transcript variants have been reported for this gene. [provided by RefSeq, Jul 2020]
- ALS
- ALS1
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~9.3 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AD
Disease ID:MONDO:0007103
Submitter: ClinGen
SOD1 was first reported in relation to autosomal dominant amyotrophic lateral sclerosis 1 (ALS) in 1993 (Rosen DR, et al., 1993, PMID: 8446170). Genetic linkage analysis performed with 13 ALS families for 10 DNA markers confirmed the presence of a FALS gene on chromosome 21. The highest total 2-point LOD score for all families was 4.33, obtained at a distance of 10 CM from the marker D21S223 and a multipoint score of 6.50 was obtained with the markers D21S213, D21S223, D21S167, and FALS for 5 chromosome 21- linked ALS families (PMID: 7913294). ALS is a neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. SOD1 encodes superoxide dismutase which has a tendency to form aggregates, and recent work has highlighted oligomers, specifically trimeric forms as the neurotoxic species (PMID: 26719414). Evidence supporting this gene-disease relationship includes case-level data and experimental data. More than 155 mutations in SOD1 have been found and associated with ALS, including single point mutations, truncations, deletions, and insertions in the protein (reviewed in PMID: 2368712). This curation includes 35 variants in this gene that have been reported in 35 probands in 3 publications (PMIDs: 8446170, 22292843, 8004110). A few mechanisms of disease implicated with SOD1 mutations are protein misfolding, proteasome impairment, oxidative stress, oligodendrocyte degeneration, and mitochondrial dysfunction. Experimentally, this gene-disease relationship is supported by the alterations observed in cells expressing SOD1 variants, which support the disease mechanism or association, including the formation of trimers (PMID: 26719414), or aggregates (PMID: 19483195), and the accumulation of misfolded or unfolded proteins in the endoplasmic reticulum which induces stress (PMID: 12659845). Further support is provided by several animal models (at least 12 transgenic strains, reviewed in PMID: 21706386) including mouse (PMID: 8209258) and rat models (PMID: 11717358), which recapitulate features of ALS. More genetic and experimental evidence is available in the literature, however the maximum score of 18pts has been reached. In summary SOD1 is definitively associated with autosomal dominant amyotrophic lateral sclerosis 1. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen ALS GCEP on 07/13/2021 (SOPv8). Of note, SOD1 has also been reported in relation to progressive spastic tetraplegia and axial hypotonia. This will be curated separately from ALS per criteria outlined by the ClinGen Lumping and Splitting working group; there is a difference in molecular mechanism (gain of toxicity vs loss of function), phenotype (adult onset motor disease vs pediatric onset pan-neurodegenerative disease), and inheritance pattern (autosomal dominant vs recessive). Additionally, ALS has also been reported with biallelic SOD1 variants, specifically Scandinavian founder variant D90A, which shows both autosomal dominant and recessive patterns in different populations (Andersen et al., 1995; Al-Chalabi et al., 1998; Aguirre et al., 1999; Hand et al., 2001; Pasinelli and Brown, 2006). However, this variant may be considered a risk allele, only resulting in disease when biallelic or in combination with another risk factor, and only dominant cases were considered within this curation.
Inheritance Pattern: AD
Disease ID:MONDO:0007103
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0007103
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0004976
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0007103
Submitter: Genomics England PanelApp
Inheritance Pattern: AR
Disease ID:MONDO:0032828
Submitter: Ambry Genetics
Inheritance Pattern: AR
Disease ID:MONDO:0032828
Submitter: Labcorp Genetics (formerly Invitae)
Clinical Genomic Database (CGD)
Manifestation: Neurologic; Ophthalmologic
Intervention: General
Rationale: Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing; Evidence for pathogenicity is unclear in Keratoconus
Comments: Evidence for involvement with Keratoconus is unclear
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to SOD1 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_000454.5. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 2 | 30 | 32 | |||
| missense | 46 | 93 | 57 | 1 | 197 | |
| nonsense | 1 | 2 | 1 | 4 | ||
| start loss | 0 | |||||
| frameshift | 1 | 3 | 1 | 5 | ||
| splice donor/acceptor (+/-2bp) | 2 | 6 | 8 | |||
| Total | 48 | 100 | 67 | 31 | 0 | 246 |
Highest pathogenic variant AF is 0.00002109613
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_000445.1 | 5 | MANE Select | |
| Ensembl | ENSP00000270142.7 | 5 | MANE Select | |
| Ensembl | ENSP00000374645.4 | 5 | Standard | |
| Ensembl | ENSP00000547387.1 | 4 | Standard |
Model Organisms & Knockout Phenotypes
Observed phenotypic effects in mouse and zebrafish models
| Gene / Model | Organism | Observed Phenotype |
|---|---|---|
| sod1 | Danio rerio | Structure: trunk Quality: morphology abnormal |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Prion diseases - Homo sapiens (human)
- Doxorubicin Pathway (Cancer Cell), Pharmacodynamics
- Longevity regulating pathway - multiple species - Homo sapiens (human)
- Peroxisome - Homo sapiens (human)
- Amyotrophic lateral sclerosis (ALS) - Homo sapiens (human)
Biological Process
- activation of MAPK activity
- response to superoxide
- ovarian follicle development
- positive regulation of cytokine production
- placenta development
Molecular Function
- superoxide dismutase activity
- copper ion binding
- protein binding
- zinc ion binding
- superoxide dismutase copper chaperone activity
Cellular Component
- extracellular region
- extracellular space
- nucleus
- nucleoplasm
- cytoplasm
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000270142
- Coding exons
- 5
- Length
- 9310
- Individuals with no LoFs
- 125734
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 14
- Defined
- 125748
- p
- 0.0000557
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 0.838 | 65 | 87.0 | 0.747 | 0.00000444 | 1003 |
| Missense (PolyPhen) | 25 | 37.197 | 0.6721 | 458 | ||
| Synonymous | -1.27 | 43 | 33.6 | 1.28 | 0.00000185 | 303 |
| Loss of Function | 1.62 | 2 | 6.43 | 0.311 | 2.74e-7 | 83 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0 | 0.0 | absent |
| Latino/Admixed American | 0.00023 | 0.00023 | rare |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0 | 0.0 | absent |
| Finnish | 0 | 0.0 | absent |
| European (Non-Finnish) | 0.000035 | 0.000035 | rare |
| South Asian | 0.000065 | 0.000065 | rare |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Destroys radicals which are normally produced within the cells and which are toxic to biological systems.;
- Disease
- DISEASE: Amyotrophic lateral sclerosis 1 (ALS1) [MIM:105400]: A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5- 10% of the cases. {ECO:0000269|PubMed:10400992, ECO:0000269|PubMed:10430435, ECO:0000269|PubMed:10732812, ECO:0000269|PubMed:11369193, ECO:0000269|PubMed:11535232, ECO:0000269|PubMed:12145308, ECO:0000269|PubMed:12402272, ECO:0000269|PubMed:12754496, ECO:0000269|PubMed:12963370, ECO:0000269|PubMed:14506936, ECO:0000269|PubMed:15056757, ECO:0000269|PubMed:18301754, ECO:0000269|PubMed:18378676, ECO:0000269|PubMed:18552350, ECO:0000269|PubMed:19741096, ECO:0000269|PubMed:21220647, ECO:0000269|PubMed:21247266, ECO:0000269|PubMed:27604643, ECO:0000269|PubMed:7496169, ECO:0000269|PubMed:7501156, ECO:0000269|PubMed:7647793, ECO:0000269|PubMed:7655468, ECO:0000269|PubMed:7655469, ECO:0000269|PubMed:7655471, ECO:0000269|PubMed:7700376, ECO:0000269|PubMed:7795609, ECO:0000269|PubMed:7836951, ECO:0000269|PubMed:7870076, ECO:0000269|PubMed:7881433, ECO:0000269|PubMed:7887412, ECO:0000269|PubMed:7951252, ECO:0000269|PubMed:7980516, ECO:0000269|PubMed:7997024, ECO:0000269|PubMed:8069312, ECO:0000269|PubMed:8179602, ECO:0000269|PubMed:8351519, ECO:0000269|PubMed:8446170, ECO:0000269|PubMed:8528216, ECO:0000269|PubMed:8682505, ECO:0000269|PubMed:8907321, ECO:0000269|PubMed:8938700, ECO:0000269|PubMed:8990014, ECO:0000269|PubMed:9101297, ECO:0000269|PubMed:9131652, ECO:0000269|PubMed:9455977, ECO:0000269|PubMed:9541385}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.954
Intolerance Scores
- LoFtool
- 0.126
- RVIS EVS
- -0.08
- RVIS percentile EVS
- 47.79
Essentials
- Essential (CRISPR)
- E
- Essential (CRISPR2)
- E
- Essential (gene trap)
- E
- Indispensability pred.
- E
- Indispensability score
- 0.925
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Low | Low |
| Primary Immunodeficiency | Medium | Low | Medium |
| Cancer | Low | Low | Low |